David Shaw’s Janux Therapeutics JANX Stock Holding History

David Shaw’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.8M	Buy	1,096,509 +998,114	+1,014%	+$14.5M	0.01%	1417
2026 Q1	$1.37M	Buy	98,395 +65,688	+201%	+$901K	﹤0.01%	3197
2025 Q4	$451K	Buy	+32,707	New	+$769K	﹤0.01%	3975
2024 Q4	–	Sell	-83,989	Closed	-$3.82M	–	4624
2024 Q3	$3.82M	Sell	83,989 -13,834	-14%	-$602K	﹤0.01%	2171
2024 Q2	$4.1M	Buy	97,823 +43,185	+79%	+$2.03M	﹤0.01%	2015
2024 Q1	$2.06M	Buy	+54,638	New	+$1.19M	﹤0.01%	2611
2022 Q2	–	Sell	-11,480	Closed	-$165K	–	5541
2022 Q1	$165K	Sell	11,480 -16,291	-59%	-$267K	﹤0.01%	4915
2021 Q4	$548K	Sell	27,771 -18,385	-40%	-$385K	﹤0.01%	4352
2021 Q3	$998K	Buy	+46,156	New	+$1.33M	﹤0.01%	3599

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

David Shaw's JANX Position: Q2 2026 in Review

David Shaw increased its Janux Therapeutics (JANX) stake by 1,014% in Q2 2026, buying an estimated $14.5M and bringing the position to 1,096,509 shares worth $16.8M. The position accounts for 0.01% of the portfolio, ranked #1417.

David Shaw first reported a position in JANX in Q3 2021 and has held it in 9 quarters since. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

David Shaw held 1,096,509 shares of Janux Therapeutics worth $16.8M as of Q2 2026.
David Shaw bought 998,114 Janux Therapeutics shares in Q2 2026, an estimated $14.5M.
Janux Therapeutics made up 0.01% of David Shaw's portfolio in Q2 2026, its #1417 holding.
David Shaw first reported a position in Janux Therapeutics in Q3 2021 and has held it in 9 quarters since.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.